CSF-1 (0.4% pilocarpine HCl), a presbyopia-correcting drop candidate from Orasis, demonstrated consistent pupil restriction, which also suggests neuroadaptation in patients with presbyopia to the drop over time.
Jacob R. Lang, OD, FAAO, presented a poster at the 2023 American Academy of Optometry (AAOpt) meeting. The poster, entitled, "Persistence of Near Vision Improvement and Pupil Size: Results of the Pooled (NEAR) Phase 3 Studies of CSF-1 (0.4% pilocarpine HCl) for Presbyopia," details data on Orasis presbyopia-correcting drop candidate, which is expected to receive an FDA decision by the PDUFA date of October 22, 2023.
Editor's note: This transcript has been lightly edited for clarity.
Jacob R. Lang, OD, FAAO:
Hi, I'm Jacob Lang. I'm with Associated Eye Care in Stillwater, Minnesota and Hudson, Wisconsin. My poster is about CSF-1 and persistence of pupil change, as well as near adaptation that occurs with use of this presbyopia-correcting medication. In this research, we saw consistent pupil restriction, with pupils in the range of 2 to 3 millimeters at both one, eight, and 15 days. The percentage of 3 line responders improved from day 1 to day 8, and again from day 8 to 15.
Based on this improvement we saw over time, this may indicate nueroadaptation occurring in these presbiopic patients as they learn how this medication works and as their brains realize how to see better at near. I think this leads into further research and understanding how our brains really interact with our visual system especially, with near correction.
The future of presbyopia research is bright. I think there's a lot of demand [and] a lot of opportunity for improving our patients visions in this frustrating visual condition.